This story is from the CurrentWire archive. Coverage details reflect the last time it was updated.
ME Therapeutics Advances In Vivo CAR and Therapeutic mRNA STING Programs
VANCOUVER, British Columbia — ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company developing novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to provide a comprehensive update on its in vivo CD19/CD22-targeted chimeric antigen receptor (CAR) program, therapeutic mRNA […]
Financial Post
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from Financial Post.
In this story
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
Financial Post (financialpost.com), a Tier B publisher, filed this report on . CurrentWire published this page 21 minutes later, on .
Filed under Business · Canada · News. Topics extracted from this report, with other live CurrentWire stories mentioning each: Vancouver (none), British Columbia (1), Therapeutics Advances (none), Vivo CAR (none), STING Programs (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.